---
title: "Claseprubart (DNTH103) in Generalized myasthenia gravis: References"
description: "Reference list for the formulary evidence report on Claseprubart (DNTH103) in Generalized myasthenia gravis. 120 cited documents."
canonical: "https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-15T22:20:57-05:00"
---

# Claseprubart (DNTH103) in Generalized myasthenia gravis: References

<a id="references"></a>

## 5 References

1. [Alshekhlee et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19414721/)
2. [ANZCTR ACTRN12622001265763](https://anzctr.org.au/ACTRN12622001265763.aspx)
3. [ANZCTR ACTRN12624000352505](https://anzctr.org.au/ACTRN12624000352505.aspx)
4. [Barnett-Tapia et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13498700/)
5. [Beydoun et al. (2026)](https://investor.dianthustx.com/static-files/d2e52c9c-ad1c-43ba-ac82-de6705cdf5eb)
6. [Bkemv prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761333s008lbl.pdf)
7. [Bruckman et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11540456/)
8. [Carr et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2905354/)
9. [Cavalcante et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11187261/)
10. [Choi et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12039500/)
11. [Çipi et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12836010/)
12. [Claytor et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37114503/)
13. [ClinicalTrials.gov NCT06282159](https://clinicaltrials.gov/study/NCT06282159)
14. [ClinicalTrials.gov NCT06858579](https://clinicaltrials.gov/study/NCT06858579)
15. [ClinicalTrials.gov NCT07647510](https://clinicaltrials.gov/study/NCT07647510)
16. [Dewilde et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9890761/)
17. [Dewilde et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10499690/)
18. [Dewilde et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12062151/)
19. [Dewilde et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12178031/)
20. [Dianthus Therapeutics (2022)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-announces-first-participant-dosed-phase-1)
21. [Dianthus Therapeutics (2023)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-announces-positive-top-line-phase-1-data)
22. [Dianthus Therapeutics (2024a)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-announces-initiation-phase-2-magic-trial)
23. [Dianthus Therapeutics (2025b)](https://www.sec.gov/Archives/edgar/data/1690585/000119312525197751/d933929dex991.htm)
24. [Dianthus Therapeutics (2025c)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-highlights-new-claseprubart-data-presented)
25. [Dianthus Therapeutics (2026c)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000021/dnth-ex99_1.htm)
26. [Dianthus Therapeutics (2026d)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-announces-initiation-phase-3-emerge-trial)
27. [Dianthus Therapeutics (2026g)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000039/dnth-ex99_1.htm)
28. [Dianthus Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1690585/000095017025037131/dnth-20241231.htm)
29. [Dianthus Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm)
30. [Dianthus Therapeutics Form 10-Q (2026c)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000040/dnth-20260930.htm)
31. [Dianthus Therapeutics Form 8-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000010/dnth-20260326.htm)
32. [Dianthus Therapeutics presentation (2024a)](https://www.sec.gov/Archives/edgar/data/1690585/000095017024002707/dnth-ex99_1.htm)
33. [Dianthus Therapeutics presentation (2024b)](https://www.sec.gov/Archives/edgar/data/1690585/000095017024135775/dnth-ex99_1.htm)
34. [Dianthus Therapeutics presentation (2025a)](https://www.sec.gov/Archives/edgar/data/1690585/000119312525197751/d933929dex992.htm)
35. [Dianthus Therapeutics presentation (2025b)](https://www.sec.gov/Archives/edgar/data/1690585/000119312525262188/dnth-ex99_1.htm)
36. [Dianthus Therapeutics presentation (2026a)](https://www.sec.gov/Archives/edgar/data/1690585/000119312526009898/dnth-ex99_1.htm)
37. [Dianthus Therapeutics presentation (2026c)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000010/dnth-ex99_1.htm)
38. [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)
39. [Dimachkie et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13310587/)
40. [Dodd et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12224225/)
41. [Dresser et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8196750/)
42. [Epysqli prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761340s024lbl.pdf)
43. [EU Clinical Trials Information System 2026-525298-38-00](https://euclinicaltrials.eu/ctis-public/view/2026-525298-38-00)
44. [Gelinas et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35486970/)
45. [Gilhus et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31048702/)
46. [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)
47. [Gilhus et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13645850/)
48. [Gokhale et al. (2024)](https://investor.dianthustx.com/static-files/385658f0-0e93-4df3-8b31-a1c0077c9024)
49. [Grob et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18059039/)
50. [Gronseth et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32213645/)
51. [Grover et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13293495/)
52. [Grover et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13724412/)
53. [Habib et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38165317/)
54. [Hehir and Silvestri (2018)](https://pubmed.ncbi.nlm.nih.gov/29655448/)
55. [Herr et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10327564/)
56. [Howard (2018)](https://pubmed.ncbi.nlm.nih.gov/29266249/)
57. [Huang et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39255718/)
58. [Hughes et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10520715/)
59. [ICER (2021)](https://icer.org/wp-content/uploads/2021/03/ICER_Myasthenia-Gravis_Final-Report_102021-1.pdf)
60. [Imaavy prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761430s002lbl.pdf)
61. [Jackson et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9837342/)
62. [Jackson et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41099443/)
63. [Jacob et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40940171/)
64. [Jaretzki et al. (2000)](https://pubmed.ncbi.nlm.nih.gov/10891897/)
65. [Jiang et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41319378/)
66. [Jul Jarbæk Nielsen et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40460351/)
67. [Kaminski et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11178544/)
68. [Khateb et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12116355/)
69. [Kusner et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3531867/)
70. [Landfeldt et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32363541/)
71. [Li et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41104507/)
72. [Lien et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11144987/)
73. [Lord et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13077509/)
74. [Manolopoulos et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12522184/)
75. [Meisel et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13093530/)
76. [Mestinon prescribing information (2023)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a851795e-b7a8-40c3-9922-5e79d3eb4d92)
77. [Muppidi et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/22006686/)
78. [Muppidi et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9302997/)
79. [Myasthenia Gravis Foundation of America](https://myasthenia.org/wp-content/uploads/Portals/0/MGFA%20Classification.pdf)
80. [Narayanaswami et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7884987/)
81. [Narayanaswami et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13400517/)
82. [Parthan et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38018505/)
83. [Peric et al. (2026b)](https://www.aan.com/msa/Public/Events/AbstractDetails/61545)
84. [Peric et al. (2026c)](https://investor.dianthustx.com/static-files/e11cda18-07b8-402e-b329-145717e8dc9b)
85. [Peric et al. (2026e)](https://investor.dianthustx.com/static-files/2908a226-f34c-4b2e-9de3-69bd0bf53e0e)
86. [Pesa et al. (2026a)](https://pubmed.ncbi.nlm.nih.gov/41455461/)
87. [Pesa et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/43001852/)
88. [Phillips et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8805609/)
89. [Rodrigues et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38040629/)
90. [Rousseff (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8073361/)
91. [Rystiggo prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761286s007lbl.pdf)
92. [Salari et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8686543/)
93. [Sanders et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4977114/)
94. [Sciancalepore et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12500283/)
95. [Shelly et al. (2026)](https://investor.dianthustx.com/static-files/1c8f7991-8993-4f05-8d16-194596a7c8c4)
96. [Siddiqi et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41139802/)
97. [Silvestri et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13008238/)
98. [Smith et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42495790/)
99. [Soliris prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125166s454lbl.pdf)
100. [Suzuki et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42275909/)
101. [Tice et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10373007/)
102. [Ultomiris prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761108s046lbl.pdf)
103. [Uplizna prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761142s004lbl.pdf)
104. [Vinciguerra et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10526522/)
105. [Vissing et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7320935/)
106. [Vissing et al. (2024)](https://investor.dianthustx.com/static-files/0ec7e0cd-6d44-419f-b020-01f204c56da3)
107. [Vu et al. (2026a)](https://investor.dianthustx.com/static-files/69412f75-384a-4ca8-9dab-aa518ad98126)
108. [Vu et al. (2026b)](https://investor.dianthustx.com/static-files/2aa268f8-9efe-4897-b3e9-5c576d4f94bc)
109. [Vyvgart Hytrulo prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761304s018lbl.pdf)
110. [Vyvgart prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761195s016lbl.pdf)
111. [WHO Collaborating Centre for Drug Statistics Methodology ATC/DDD Index (2026)](https://atcddd.fhi.no/atc_ddd_index/?code=L04AJ)
112. [WHO Drug Information Recommended INN List 94 (2025)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/rl94.pdf)
113. [WHO INN monoclonal antibody nomenclature scheme (2022)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/new_mab_nomenclature-_2021rev.pdf)
114. [WHO Proposed INN List 132 (2024)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl132.pdf)
115. [Wolfe et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5189669/)
116. [Wolfe et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6774753/)
117. [Ye et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10907989/)
118. [Yoder et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39697037/)
119. [Zhdanava et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38745448/)
120. [Zilbrysq prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/216834s015lbl.pdf)

## Related pages
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics.md)
